{"filings":[{"id":3373757,"accession_number":"0001683168-26-007749","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-10-09T20:15:22+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aethlon Medical boosts authorized common shares 10x to 200M, effective Oct 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock, $0.001 par value, rises from 20,000,000 to 200,000,000 shares, amending Article V of the Articles of Incorporation.","Stockholders approved the amendment at the 2026 Annual Meeting held October 1, 2026; Certificate of Amendment filed with the Nevada Secretary of State and effective October 7, 2026.","Filing discloses no issuance, pricing, or intended use of proceeds for the newly authorized shares, and no corresponding financing was announced.","Certificate of Amendment attached as Exhibit 3.1; filing signed October 9, 2026 by CEO and CFO James B. Frakes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3264478,"accession_number":"0001683168-26-007613","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K/A","filed_at":"2026-10-05T20:10:36+00:00","items":["5.07"],"status":"ready","headline":"Aethlon Medical corrects 8-K: proposal to authorize 20M preferred shares failed at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal No. 7 received 204,122 votes for, 9,529 against, 1,555 abstentions and 184,547 broker non-votes.","Approval required a majority of the 711,136 shares outstanding on the Aug 10, 2026 record date, or at least 355,569 affirmative votes; only 204,122 were cast in favor.","The Articles of Incorporation were not amended and no preferred stock was authorized; the original Oct 1, 2026 Form 8-K had incorrectly reported approval.","The failed amendment would have authorized 20,000,000 preferred shares, $0.001 par value, and let the Board set series terms, powers and preferences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3210440,"accession_number":"0001683168-26-007542","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-10-01T21:24:17+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Aethlon Medical stockholders approve charter amendments and 2020 Equity Incentive Plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increasing authorized common stock from 20,000,000 to 200,000,000 shares and authorizing 20,000,000 preferred shares, $0.001 par value.","Stockholders approved adding 100,000 shares to the 2020 Equity Incentive Plan; the proposal received 204,289 votes for and 8,407 against.","Stockholders approved issuing up to 1,126,602 common shares upon exercise of July 2026 Common Warrants and Placement Agent Warrants under Nasdaq Rule 5635(d).","Annual Meeting held October 1, 2026; 399,752 of 711,136 shares (56.21%) represented by proxy or virtually, establishing a quorum.","Five directors elected: Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2917196,"accession_number":"0001683168-26-007206","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-09-17T12:03:36+00:00","items":["1.01","5.01","7.01","9.01"],"status":"ready","headline":"Aethlon Medical to merge with North Immunology in $150M all-stock deal; $180M PIPE backs NOR-101","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock merger values North Immunology at $150M and Aethlon at $16.5M; closing expected by June 17, 2027.","North Immunology stockholders to own ~95.25% of combined company; Aethlon holders ~4.75%.","Oversubscribed $180M private placement ($146M cash + $34M notes) funds operations into 2H 2028.","NOR-101 (IL-13 x IL-18 bispecific) for atopic dermatitis: Phase 1a Q1 2027, Phase 1b/2b data 2028.","Legacy Aethlon assets to receive contingent value rights (CVRs) with no guaranteed payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2862757,"accession_number":"0001683168-26-007126","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-09-15T12:17:35+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aethlon Medical amends exec severance to lump-sum on change in control for CEO/CFO and CMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Sept 11, 2026, Aethlon amended employment agreements of CEO/CFO James B. Frakes and CMO Steven P. LaRosa.","Change-in-control severance payments will now be paid as a single lump sum instead of installments.","Health care continuation payments also become lump-sum, fixed once payable, not reduced by new coverage.","Amendment does not alter amount, calculation, or eligibility for severance benefits.","Frakes serves as CEO/CFO; LaRosa as CMO; no changes to their base pay or other terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2560516,"accession_number":"0001683168-26-006815","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-08-31T13:15:13+00:00","items":["8.01"],"status":"ready","headline":"Aethlon Medical: all pre-funded warrants exercised; 1,604,095 shares outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Aug 28, 2026, Aethlon Medical has 1,604,095 common shares outstanding.","All previously outstanding pre-funded warrants have been exercised.","CEO and CFO James B. Frakes signed the 8-K on Aug 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2244358,"accession_number":"0001683168-26-006344","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-08-13T20:15:36+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical reports Q1 FY2027 results; cash $4.9M, raises $4M post-quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents ~$4.9M as of June 30, 2026; raised ~$4.0M gross in public offering after quarter-end.","Operating expenses decreased 11.9% to ~$1.6M vs $1.8M in prior-year quarter.","First participant dosed in third/final cohort of Phase 1 oncology study in Australia; early biomarker signals support Hemopurifier.","Long COVID manuscript accepted for publication in International Journal of Molecular Sciences.","Company believes cash resources sufficient to fund operations for at least next 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1977518,"accession_number":"0001683168-26-005850","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-07-31T12:00:57+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Aethlon Medical announces 1-for-5 reverse stock split effective July 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved by board; no stockholder vote required under Nevada law.","Effective 10:00 a.m. ET on July 31, 2026; split-adjusted trading begins August 4, 2026 under symbol AEMD.","Pre-split shares: 3,249,569; post-split approx 649,914; authorized shares reduced from 100M to 20M.","No fractional shares issued; rounding up to whole share; CUSIP changes to 00808Y703.","Purpose: dilution management and continued compliance with Nasdaq minimum bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1507561,"accession_number":"0001683168-26-005338","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-07-07T23:07:31+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aethlon Medical raises $4.0M in follow-on offering priced at $0.71/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.0M from sale of common stock, pre-funded warrants, and warrants; net proceeds ~$3.335M.","Offering includes 5.63M common warrants exercisable at $0.71 per share, subject to stockholder approval.","Maxim Group acted as sole placement agent; received 6.25% cash fee and 225,320 placement agent warrants.","Proceeds to be used for working capital, R&D, clinical trials, and potential acquisitions.","Lock-up agreements for officers and directors for 90 days; company restricted from issuing securities for 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":973084,"accession_number":"0001683168-26-004707","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-06-10T20:15:25+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical reports FY2026 net loss $7.2M, cash $5.0M; oncology study enters final cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.2M vs $13.4M prior year; operating expenses down 21.9% to $7.3M.","Cash $5.0M at March 31; subsequent $1.85M raised via ATM program.","Australian oncology study advanced to Cohort 3; first patient treated in final dosing cohort.","Patents issued in US and Europe for Hemopurifier in long COVID/coronavirus, extending protection to 2040s.","Preclinical studies for rheumatoid arthritis and chronic kidney disease underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843876,"accession_number":"0001683168-26-004540","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-06-04T13:00:39+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon Medical files Amendment No. 1 to Prospectus Supplement; up to $542,716 remaining in ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Amendment No. 1 to Prospectus Supplement under S-3 Registration Statement (File No. 333-292405) on June 4, 2026.","Remaining aggregate offering price of $542,716 in common stock may be sold under ATM Agreement with H.C. Wainwright & Co.","Previously sold $1,849,457 in shares under the same Prospectus Supplement before the amendment.","As of June 1, 2026, shares outstanding: 2,344,886; public float: 2,337,629 shares held by non-affiliates.","All other terms of the offering and ATM Agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115368,"accession_number":"0001683168-26-001887","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aethlon Medical discloses 1,569,110 shares outstanding after all pre-funded warrants exercised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of March 16, 2026, Aethlon Medical has 1,569,110 shares of common stock outstanding.","All previously outstanding pre-funded warrants have been exercised as of that date.","The share count update follows recent exercises of pre-funded warrants, per Item 8.01 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115367,"accession_number":"0001683168-26-001259","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Aethlon Medical stockholders approve increase in authorized shares to 100M and equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized common shares from 6M to 100M (495,950 for, 58,624 against).","Stockholders approved 2020 Equity Incentive Plan amendment adding 100,000 shares (291,835 for, 18,607 against).","Five directors elected; Haskell & White LLP ratified as auditor for FY ending March 31, 2026.","Approved issuance of up to 1.66M shares upon warrant exercise and ~368k shares upon warrant inducement (Dec 2025 agreements).","All proposals passed; quorum of ~57% of outstanding shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115366,"accession_number":"0001683168-26-000959","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical Q3 FY2026: cash $7.0M; operating loss $2.06M up 13.6% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash balance of ~$7.0M as of Dec 31, 2025; no revenue reported.","Q3 operating loss of $2.06M vs $1.81M in prior year, driven by higher payroll costs.","Nine-month operating expenses down 26.9% to $5.36M from $7.34M YoY.","Cohort 2 of Australian oncology trial progressing; Hemopurifier compatibility study with SLAMB system underway.","Preclinical Long COVID data published on bioRxiv; submitted for peer review."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115365,"accession_number":"0001683168-26-000528","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aethlon removes shareholder approval condition; pre-funded warrants immediately exercisable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendments to SPA and Pre-Funded Warrant remove Nasdaq 5635 shareholder approval requirement, effective Jan 22, 2026.","Pre-funded warrants issued to Armistice Capital (institutional investor) are now immediately exercisable.","No other terms of the original December 2025 agreements were changed.","Company's common stock trades on Nasdaq under ticker AEMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131773,"accession_number":"0001683168-25-008953","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","3.03","7.01","9.01"],"status":"ready","headline":"Aethlon Medical prices $3.3M PIPE and warrant inducement at $4.03/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.3M from private placement and warrant inducement; closing expected Dec 8, 2025.","PIPE: 596,452 shares (or pre-funded warrants) at $4.03/unit plus 1,043,791 warrants exercisable at $4.03.","Warrant inducement: reduced exercise price to $4.03 on existing March/September 2025 warrants; new warrants for 368,471 shares.","New warrants exercisable only after shareholder approval and expire 5.5 years from that date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131772,"accession_number":"0001683168-25-008257","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.","Operating loss narrowed to $1.5M from $2.8M in the prior-year quarter.","Nasdaq compliance resolved; AEMD remains listed on the Capital Market.","Recruitment began for Cohort 2 of Australian Hemopurifier oncology trial with pembrolizumab/nivolumab.","Long COVID research with UCSF continues; manuscript in preparation for peer-reviewed journal."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131771,"accession_number":"0001683168-25-008001","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aethlon Medical regains Nasdaq minimum bid price compliance, matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 5, 2025 confirming regained compliance with $1.00 minimum bid price rule.","Previously non-compliant on Oct 16, 2025 after stock closed below $1.00 for 30 consecutive business days.","Compliance achieved by maintaining closing bid price of at least $1.00 for ten consecutive business days.","Nasdaq confirms the matter is closed; no further action required for continued listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131770,"accession_number":"0001683168-25-007719","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aethlon Medical receives Nasdaq delisting notice for bid price below $1.00, requests hearing, implements reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 16, 2025 for non-compliance with minimum bid price of $1.00 over 30 consecutive business days.","Company requested a hearing before Nasdaq Hearings Panel, automatically staying delisting pending decision.","Implemented 1-for-10 reverse stock split effective Oct 16, trading Oct 20, to regain compliance.","Stock continues to trade on Nasdaq Capital Market under symbol AEMD while hearing is pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131769,"accession_number":"0001683168-25-007586","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Aethlon Medical (AEMD) files 1-for-10 reverse stock split effective Oct 16, 2025; split-adjusted trading Oct 20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 10:00 a.m. ET Oct 16, 2025; split-adjusted trading begins Oct 20 under symbol AEMD.","Authorized shares reduced from 60M to 6M; outstanding shares from ~7.6M to ~761k (no fractional shares, rounding up).","Split intended to maintain Nasdaq Listing Rule 5550(a)(2) compliance and manage dilution.","No stockholder approval required under Nevada law; board approved per NRS Section 78.207.","CUSIP changes to 00808Y604; Computershare as transfer agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148365,"accession_number":"0001683168-25-006917","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aethlon Medical reports 7,373,156 shares outstanding after best-efforts offering","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Shares outstanding: 7,373,156 as of September 12, 2025.","Result of recently completed best-efforts public offering (no pricing or size disclosed).","No other operational or financial updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148364,"accession_number":"0001683168-25-006788","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aethlon Medical prices $4.5M public offering of common stock and warrants at $0.90/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.5M; net to company ~$3.9M after placement agent fees and expenses.","Offering includes 5M shares (or pre-funded warrants) and 5M warrants exercisable at $0.90 for 5 years.","Maxim Group acted as exclusive placement agent; 6.25% cash fee ($281,250) and 200,000 warrants.","Net proceeds to be used for working capital, clinical trial and R&D expenses.","Officers and directors subject to 60-day lock-up; company has 90-day issuance standstill."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148363,"accession_number":"0001683168-25-006360","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aethlon Medical releases updated corporate presentation; no financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation furnished as Exhibit 99.1 and available on company website.","Presentation title references The Hemopurifier® but no specific data or milestones provided in the filing.","No financial, operational, or clinical updates contained in the available exhibit text.","Presentation is furnished under Regulation FD and not filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148362,"accession_number":"0001683168-25-006042","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical reports Q1 FY2026 operating loss of $1.8M; cancer trial advances to second cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating loss narrowed to $1.8M from $2.6M YoY; cash balance $3.8M at June 30, 2025.","First cohort completed in Australian Hemopurifier cancer trial; DSMB approves second cohort with two treatments.","Amended protocol broadens eligibility to any anti-PD-1 regimen; preclinical data show 98.5% removal of platelet-derived EVs.","India oncology study dropped due to extended timeline; Long COVID research with UCSF presented at Keystone Symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167142,"accession_number":"0001683168-25-004784","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical FY2025 op loss $9.3M (down 26% YoY); Hemopurifier cancer trial treats first 3 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.","First three patients treated in Hemopurifier cancer trial in Australia; DSMB safety review triggered.","Received Indian regulatory approval (CDSCO) to initiate similar oncology trial at Medanta Medicity Hospital.","Preclinical study showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier treatment.","Non-cash warrant inducement charge of $4.6M; ERTC other income $324,450."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167141,"accession_number":"0001683168-25-004248","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aethlon Medical set 1-for-8 reverse stock split effective June 6, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio: 1-for-8; effective 5:00 PM ET June 6, 2025.","Trading on split-adjusted basis begins June 9, 2025 on Nasdaq.","No fractional shares issued; stockholders receive full share for fractions.","New CUSIP number: 00808Y 505.","Proportionate adjustments to options, warrants, and equity plan reserves."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167140,"accession_number":"0001683168-25-003490","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aethlon Medical stockholders approve reverse stock split authorization and warrant issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at ratio 1:5 to 1:12, board to determine timing by May 13, 2026.","Approval granted for issuance of shares upon exercise of Inducement Warrants and Reset of Exercise Price provision.","All three proposals passed; adjournment proposal approved but not needed as quorum and votes sufficient.","Approximately 38.78% of outstanding shares (6.2M of 16.1M) represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184504,"accession_number":"0001683168-25-001631","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Aethlon Medical raises ~$2.3M via warrant exercise inducement, issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $2,316,320 from exercise of 6,200,000 Existing Warrants at reduced price of $0.3736/share.","Holder received new unregistered warrants to purchase 200% of the exercised shares at $0.3736, exercisable after 6 months for 5.5 years.","Company issued 6,200,000 shares of common stock; net proceeds for working capital and general corporate purposes.","Stockholder approval required to retroactively approve the reset exercise price provision in the new warrants.","Placement agent Maxim Group LLC received 6.0% cash fee ($138,979) plus $15,000 expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184503,"accession_number":"0001683168-25-000957","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical Q3 net loss narrows to $1.8M; first patient treated in Hemopurifier cancer trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash balance $4.8M at Dec 31, 2024; operating expenses down 50% YoY to $1.8M.","First Hemopurifier treatment completed Jan 29, 2025 at Royal Adelaide Hospital with no device-related issues.","Net loss improved to $1.8M ($3.5M Q3 2023) due to cost cuts and lower separation expenses.","Protocol amendment approved at all three Australian sites to accelerate enrollment by removing run-in period.","Third clinical site (Genesis Care/Royal North Shore) to activate Feb 14, 2025; India site awaits CDSCO approval."],"consensus_eps_estimate":-3.7366,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184502,"accession_number":"0001683168-25-000150","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aethlon Medical gets 180-day Nasdaq extension through June 23, 2025 for bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received 180-day extension from Nasdaq until June 23, 2025 to regain $1.00 minimum bid price compliance.","Stock must close at $1.00+ for at least 10 consecutive trading days to regain compliance; non-compliant since June 2024.","Failure to regain compliance by June 23, 2025 may lead to delisting; Company could appeal to hearings panel.","Company intends to monitor bid price and consider available options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201092,"accession_number":"0001683168-24-008868","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon Hemopurifier removes 99% of H5N1 in vitro; monitoring bird flu outbreak","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In vitro study with scaled-down Hemopurifier showed 99% removal of H5N1 virus after 6 hours.","Device has not yet been used in human patients for H5N1; 38 patients treated for other enveloped viruses.","Hemopurifier holds FDA breakthrough device designation for life-threatening viruses with no effective treatment.","Company monitoring cases and engaging with hospitals, California, and FDA on potential use.","CDC recommends antivirals for H5N1; resistance observed in some hospitalized patients, suggesting need for novel therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201091,"accession_number":"0001683168-24-007972","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical reports Q2 net loss $2.8M; enrolls first 2 patients in Hemopurifier cancer trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $2.8M from $3.0M YoY; cash balance $6.9M as of Sep 30, 2024.","Enrolled first two patients in safety/feasibility Hemopurifier trial for solid tumors at Royal Adelaide Hospital.","Two Australian sites open; third site ethics approval pending; India site approved at Medanta Medicity.","James Frakes permanently appointed CEO, previously interim since Nov 2023.","Operating expenses decreased 9% to $2.9M due to cost-cutting and legal fee reductions."],"consensus_eps_estimate":-8.772,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201090,"accession_number":"0001683168-24-007858","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon Medical enrolls first patient in Hemopurifier cancer trial for solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient enrolled Oct 29, 2024 at Royal Adelaide Hospital; eligibility confirmed Nov 8.","Trial is safety, feasibility, dose-finding for Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.","Two-month run-in on anti-PD-1 therapy; if no tumor improvement, patient treated with Hemopurifier.","Trial targets 9-18 patients; primary endpoint is adverse events and safety lab changes.","Exploratory endpoints measure extracellular vesicle reduction and T cell activity improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201089,"accession_number":"0001683168-24-006896","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aethlon Medical appoints James B. Frakes as permanent CEO; COO Guy F. Cipriani departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James B. Frakes, serving as interim CEO since Nov 7, 2023, appointed permanent CEO effective Oct 3, 2024; remains CFO and Board member.","Guy F. Cipriani departed as COO effective Oct 3, 2024; departure not related to financial or reporting disagreements.","Cipriani eligible for 12 months' severance and separation benefits subject to execution of release agreement.","Company intends to enter amended employment agreement with Frakes for his CEO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201088,"accession_number":"0001683168-24-006850","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Aethlon Medical shareholders approve 3M share increase to 2020 Equity Plan; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 3,000,000 to total 3,364,256 shares.","Five directors elected: Broenniman, Frakes, Gikakis, Rossetti, Shah, each with over 2.9M votes for.","Ratification of Haskell & White LLP as independent auditor approved: 4.70M for, 163,731 against.","Non-binding advisory vote on executive compensation approved: 2.76M for, 245,575 against.","Plan amendment effective September 27, 2024, after receiving stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217114,"accession_number":"0001683168-24-006522","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon receives ethics approval for Hemopurifier cancer trial in India; enrollment targeted Q4 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Medanta Institutional Ethics Committee approved safety, feasibility, dose-finding trial of Hemopurifier in solid tumors not responding to anti-PD-1 antibodies.","Trial at Medanta Medicity Hospital, Gurugram, India; Dr. Ashok K. Vaid and Dr. Puneet Sodhi as investigators.","Patient recruitment expected Q4 2024; primary endpoint is safety, with exploratory EV reduction analyses.","This adds to prior Australian ethics approvals and DCGI No Objection Certificate for the oncology trial.","Hemopurifier designed to remove tumor-derived extracellular vesicles that may drive resistance to PD-1 inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217113,"accession_number":"0001683168-24-005697","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.","Cash balance $9.1M as of June 30, 2024.","Ethics approvals granted for Hemopurifier safety study in solid tumor patients on anti-PD-1 therapy.","Expects to open patient enrollment in October 2024; additional sites anticipated by end of 2024.","COVID-19 trial in India remains open; one patient treated to date."],"consensus_eps_estimate":-10.302,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217112,"accession_number":"0001683168-24-005445","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon Medical receives second ethics approval for Hemopurifier cancer trial in Australia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bellberry Human Research Ethics Committee granted full ethics approval to Pindara Private Hospital for Hemopurifier trial in solid tumors not responding to anti-PD-1 antibodies.","This is the second ethics committee approval; the first came from Royal Adelaide Hospital in June 2024.","The trial will be conducted by Dr. Marco Matos at Pindara Private Hospital in Queensland, Australia.","Next steps include Research Governance Office approval, then Site Initiation Visits before patient enrollment can begin.","Primary endpoint is safety; the trial plans to enroll 9–18 patients and will explore extracellular vesicle reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217111,"accession_number":"0001683168-24-004660","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Aethlon Medical dismisses Baker Tilly, engages Haskell & White as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Baker Tilly US, LLP effective July 1, 2024; audit committee approved.","Baker Tilly's FY2024 report included a going concern explanatory paragraph; no disagreements or reportable events.","Engaged Haskell & White LLP as independent auditor for FY2025 ending March 31, 2025.","No prior consultations with Haskell & White on accounting or auditing matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236877,"accession_number":"0001683168-24-004526","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aethlon Medical reports FY2024 net loss of $12.2M; cash at $9.1M; oncology trial approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.2M for FY ended March 31, 2024, compared to $12.0M in FY2023.","Cash balance of $5.4M at March 31, 2024, increased to $9.1M as of June 25, 2024.","Received HREC ethics approval for Hemopurifier safety/feasibility oncology trial in Australia, valid through 2027.","FDA approved internal manufacturing facility in April 2024.","COVID-19 trial in India remains open with one patient treated; monitoring H5N1 avian flu situation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236876,"accession_number":"0001683168-24-003812","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aethlon Medical reports 9,229,725 shares outstanding after public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Outstanding shares as of May 23, 2024 total 9,229,725, updated after a best-efforts public offering.","The filing confirms completion of a recent equity financing, though no deal size or terms are disclosed.","No other material events or financial results were announced in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236875,"accession_number":"0001683168-24-003612","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon Medical prices $4.7M public offering of common stock and warrants at $0.58 per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.7M; net proceeds ~$3.84M after placement agent fees and expenses.","Offering consists of 8.1M shares (or pre-funded warrants) plus Class A and B warrants to buy 8.1M shares each, all at $0.58 per unit.","Class A warrants expire in 5 years, Class B in 1 year; pre-funded warrants exercisable at $0.001 per share.","Maxim Group LLC acted as exclusive placement agent with 6.5% cash fee plus $100K expense reimbursement.","Net proceeds to fund clinical trials, R&D, capex, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236874,"accession_number":"0001683168-24-003191","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon Medical reports positive in vitro Hemopurifier data for removing extracellular vesicles from cancer plasma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In vitro binding study of Hemopurifier shows removal of extracellular vesicles (EVs) directly from cancer patient plasma.","Data supports planned Phase 1 trial in solid tumor patients on anti-PD-1 therapies (Keytruda/Opdivo).","Descriptive statistics from CRO NAMSA confirm EV removal; PD-L1+ EV subset inconclusive due to low counts.","Next step: submit data to Ethics Committees in Australia and India to initiate Phase 1 oncology studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236873,"accession_number":"0001683168-24-002672","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon Medical updates corporate presentation for April 2024; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation made available for investor meetings; filed as Exhibit 99.1.","Exhibit contains only a cover slide; no specific pipeline, financial, or operational updates provided.","No material changes from prior disclosures are evident in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254485,"accession_number":"0001683168-24-000985","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aethlon Medical Q3 net loss widens to $3.6M; expenses up 25% on CEO separation costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.6M for fiscal Q3 ended Dec 31, 2023, vs $2.8M a year ago.","Operating expenses $3.6M (+25% YoY), driven by $873K in former CEO separation costs.","Cash balance $8.0M as of Dec 31, 2023; company focusing on expense reduction.","Received DCGI clearance in India for phase 1 trial of Hemopurifier in solid tumors.","In vitro binding study results inconclusive; engaging third-party labs for independent assays."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271951,"accession_number":"0001683168-23-009061","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K/A","filed_at":"2023-12-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aethlon Medical sets compensation for Frakes as Interim CEO ($500K salary) and Cipriani as COO ($390K)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Frakes appointed Interim CEO effective Nov 7, 2023; base salary raised from $360K to $500K while in role.","Guy Cipriani appointed SVP & COO effective Nov 7, 2023; base salary set at $390K; resigned from Board.","Frakes also remains CFO and joined Board; salary may revert upon hiring of permanent CEO.","Cipriani resigns from Board per terms; reports to Interim CEO then to new CEO when appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271955,"accession_number":"0001683168-23-008454","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Dr. Charles Fisher resigns from Aethlon board Nov 27; $460k severance, 50% option acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Charles J. Fisher, Jr. resigns as director effective Nov 27, 2023; previously stepped down as CEO Nov 7.","Severance includes 12 months base salary ($460,000 total), paid over regular payroll schedule.","50% of outstanding unvested time-based stock options will accelerate and become fully vested.","COBRA healthcare premium reimbursement provided for up to 12 months post separation.","James B. Frakes, previously appointed Interim CEO, remains as interim CEO and CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271954,"accession_number":"0001683168-23-008131","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aethlon Medical reports Q2 net loss down to $3.0M; CEO Fisher replaced by Frakes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for fiscal Q2 2023: $3.0M vs $3.8M in prior year; operating expenses decreased 13.4% to $3.2M.","Cash balance $10.2M as of Sept 30, 2023.","CEO Charles Fisher replaced by James Frakes (Interim CEO, retains CFO role); Guy Cipriani becomes COO.","Received DCGI clearance in India for Phase 1 Hemopurifier trial in solid tumors on anti-PD-1 therapy.","Hemopurifier supply disruption continues; working with FDA for second GNA supplier; new San Diego facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271953,"accession_number":"0001683168-23-007912","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aethlon Medical appoints James B. Frakes as Interim CEO; Charles J. Fisher Jr. departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles J. Fisher Jr., M.D. departed as CEO effective Nov 7, 2023; Guy F. Cipriani resigned as director.","James B. Frakes appointed as Interim CEO and Board member, retains CFO role.","Guy F. Cipriani appointed as Senior VP and COO; resigned from Board.","Frakes' base salary $360,000 (set Jan 2023); eligible for discretionary bonus.","Company plans amended employment agreements for Frakes and Cipriani."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271952,"accession_number":"0001683168-23-006959","cik":882291,"company_name":"AETHLON MEDICAL INC","ticker":"AEMD","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aethlon completes 1-for-10 reverse stock split to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved by stockholders and board; ratio 1-for-10.","Effective 5:00 p.m. ET on October 4, 2023; trading begins on split-adjusted basis October 5.","Post-split outstanding shares approximately 2.5 million; new CUSIP 00808Y406.","Purpose: meet Nasdaq minimum bid price requirement and continue capital market access.","No fractional shares issued; stockholders receive full share for any fractional interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4817168.326530612,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-10-04T23:59:59+00:00|271952"}